2018 CHF | Restated 2017 CHF | ||
| 01.01.18 – 30.06.18 | 01.01.17 – 30.06.17 | ||
| Net profit | –2,197,579 | 13,984,884 | |
| Depreciation of fixed assets and amortisation of intangible assets | 7,269,124 | 5,916,798 | |
| Impairment of shareholdings | 2,849,490 | 0 | |
| Currency effect on the Lithuania sale | 3,017,328 | 0 | |
| Net interest expense | 325,640 | 632,839 | |
| Other non-cash adjustments | –380,803 | –538,037 | |
| Change in long-term provisions | 472,271 | 633,848 | |
| Accounting losses (profits) from sales of fixed assets | 101,344 | –16,658 | |
| Income from associates and joint ventures | 298,421 | –219,360 | |
| Cash flow from operating activities before changes in working capital | 11,755,236 | 20,394,313 | |
| As % of net sales revenue | 4.17% | 6.74% | |
| Change in accounts receivables | 5,145,952 | –23,830,894 | |
| Change in accounts receivables from related parties | –10,446,434 | –2,659,980 | |
| Change in accounts receivables from associated parties | –1,904,248 | –740,625 | |
| Change in other short-term receivables | –4,390,079 | –9,441,468 | |
| Change in other short-term receivables from related parties | 0 | –4,861 | |
| Change in inventories | –25,770,468 | –9,976,894 | |
| Change in prepayments | 1,352,828 | –4,164,792 | |
| Change in liabilities from deliveries and services | –19,761,874 | –4,672,584 | |
| Change in other short-term liabilities | –236,308 | 4,202,386 | |
| Change in other short-term liabilities to related parties | 1) | –69,689,751 | –8,038,238 |
| Change in deferred income | –360,156 | 1,690,826 | |
| Change in net current assets | –126,060,538 | –57,637,123 | |
| Cash flow from operating activities | –114,305,302 | –37,242,810 | |
| In % of net sales revenue | –40.59% | –12.32% | |
| Investments in fixed assets | –19,298,814 | –30,708,737 | |
| Divestments of fixed assets | 24,261 | 27,823 | |
| Investments in intangible assets | –340,055 | –198,943 | |
| Investments in/divestment of long-term financial assets | –378,949 | 22,029 | |
| Net cash flow from the purchase (-) / sale (+) of investments | 2) | –31,661,208 | 0 |
| Interest and dividends received | 230 | 670 | |
| Cash flow from investing activities | –51,654,534 | –30,857,157 | |
| Free cash flow | –165,959,836 | –68,099,967 | |
| In % of net sales revenue | –58.94% | –22.52% | |
| Change in short-term financial liabilities | –961,805 | –6,789,179 | |
| Change in long-term financial liabilities | 131,240,610 | –31,589,574 | |
| Additions/disposals of minority interests in capital and profit | 0 | –40,486 | |
| Mandatory convertible bond | 0 | 87,485,000 | |
| Capital increase | 0 | –1,420,881 | |
| Change in capital of subsidiaries | 0 | 18,750 | |
| Sale (purchase) of treasury shares net cash flow | 3,329,006 | –1,745,768 | |
| Interest paid | –4,382,801 | –1,791,071 | |
| Dividend payments | –5,598,980 | –5,336,891 | |
| Cash flow from financing activities | 123,626,029 | 38,789,899 | |
| Currency translation | –61,241 | –56,701 | |
| Net change in cash and cash equivalents | –42,395,047 | –29,366,769 | |
| Cash and cash equivalents at 1 January | 63,860,406 | 67,707,898 | |
| Cash and cash equivalents at 30 June | 21,465,358 | 38,341,129 | |
1) Purchase price payment Pharmalys Laboratories SA
2) Acquisition of Bimbosan AG and sale of HOCHDORF Baltic Milk UAB